Vimarsana
Biggest News Aggregation in the World

Prospective Data News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Prospective Data. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Prospective Data Today - Breaking & Trending Today

Radial Access Is Safe, Effective for Peripheral Interventions: R2P Registry - Vimarsana News

Radial Access Is Safe, Effective for Peripheral Interventions: R2P Registry

The radial-to-peripheral approach is a viable alternative to femoral access for many procedures, Andrew Klein says.

Source: tctmd.com
What is the impact of COVID-19 on maternal, fetal, and neonatal characteristics? - Vimarsana News

What is the impact of COVID-19 on maternal, fetal, and neonatal characteristics?

In a new study, researchers assessed the impact of early onset COVID-19 on maternal, fetal, and neonatal characteristics.

Johnson & Johnson : New Data from Phase 3 GLOW Study Show Fixed-Duration Treatment with IMBRUVICA® (ibrutinib) Plus Venetoclax Demonstrated Deeper and Sustained Undetectable Minimal Residual Disease Outcomes in First-Line Chronic Lymphocytic Leukemia - Vimarsana News

Johnson & Johnson : New Data from Phase 3 GLOW Study Show Fixed-Duration Treatment with IMBRUVICA® (ibrutinib) Plus Venetoclax Demonstrated Deeper and Sustained Undetectable Minimal Residual Disease Outcomes in First-Line Chronic Lymphocytic Leukemia

Updated results from the MRD cohort of the Phase 2 CAPTIVATE study also highlight potential for treatment-free remissions with IMBRUVICA® plus venetoclax in an oral presentation at ASH... | December 11, 2021

AbbVie to Highlight New Advances in Blood Cancer Research and Expanding Oncology Pipeline at 63rd ASH Annual Meeting - Vimarsana News

AbbVie to Highlight New Advances in Blood Cancer Research and Expanding Oncology Pipeline at 63rd ASH Annual Meeting

ABBVie will present results from nearly 30 abstracts across eight types of cancer during the upcoming American Society of Hematology Annual Meeting in Atlanta, Georgia . "We are dedicated to transforming standards of care for people living with blood cancers," said Mohamed Zaki M.D., Ph.D, vice president and global head of oncology development, AbbVie. "The data we are presenting at the ASH Annual Meeting build on ...

AbbVie to Highlight New Advances in Blood Cancer Research and Expanding Oncology Pipeline at 63rd ASH Annual Meeting - Vimarsana News

AbbVie to Highlight New Advances in Blood Cancer Research and Expanding Oncology Pipeline at 63rd ASH Annual Meeting

/PRNewswire/ -- AbbVie (NYSE: ABBV) will present results from nearly 30 abstracts across eight types of cancer during the upcoming American Society of...